CFO
MYGN icon

CVA Family Office’s Myriad Genetics MYGN Stock Holding History

CVA Family Office’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-22
Closed -$603 – 1324
2024
Q3 		$603 Hold
22
– – ﹤0.01% 1156
2024
Q2 		$538 Buy
+22
New +$483 ﹤0.01% 1174

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

CVA Family Office's MYGN Position: Q4 2024 in Review

CVA Family Office sold out of Myriad Genetics (MYGN) in Q4 2024, closing a stake of 22 shares — an estimated $603 sold.

CVA Family Office first reported a position in MYGN in Q2 2024 and held it in 2 quarters. The position peaked at $603 in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2024.

  • CVA Family Office reported no remaining Myriad Genetics position as of Q4 2024 after selling out during the quarter.
  • CVA Family Office sold 22 Myriad Genetics shares in Q4 2024, an estimated $603.
  • CVA Family Office first reported a position in Myriad Genetics in Q2 2024 and held it in 2 quarters.
  • CVA Family Office's Myriad Genetics position peaked at $603 in Q3 2024.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2024.

Based on CVA Family Office's 13F filing for Q4 2024, filed 7 Jan 2025.